Photo: JOHN THYS / AFP / Getty Images
This Friday, the laboratory Pfizer officially announced the results of their clinical trial conducted on the pill they have developed to try to combat Covid-19 It is capable of reducing up to 89% the risks of hospitalization and deaths in people who have been infected with the disease.
Pfizer’s pill against Covid-19 is called Paxlovid, According to various US and international media, 1,219 patients who were infected with the virus participated in the study, who were given this drug along with another antiviral, and the combination reduced by this percentage the development of a severe coronavirus disease, in compared with those patients who were only given placebos.
Also, the study took into account other variables, in particular those risk factors that patients had for developing a mild or moderate disease, such as obesity or age.
Similarly, it is detailed in the report that 0.8% of those who received the Pfizer drug within three days of the onset of symptoms were hospitalized and none had died 28 days after treatment. This was compared with a 7% hospitalization rate for placebo patients, in whose group there were 7 deaths.
How does Paxlovid, Pfizer’s pill against Covid-19 work?
What this Pfizer drug does is that it attaches itself to an enzyme called protease to prevent the coronavirus virus from replicating in the body. In fact, some drugs to treat HIV and hepatitis C work in a similar way.
The Paxlovid developers relied on a formula created almost a decade ago to develop an experimental antiviral drug after the SARS (Severe Acute Respiratory Syndrome) epidemic in late 2002. The old drug had to be administered intravenously. But in July of last year, Pfizer researchers modified the original molecule and created a new compound that turned out to be very potent against Covid-19 and other coronaviruses in laboratory tests and could be used as a pill.
This pill should be taken 2 times a day for 5 days and It must be combined with a second medicine called ritonavir, as this helps the Paxlovid compound to stay in the bloodstream for longer.
Pfizer also indicated that it plans to submit the results of these interim trials to the US Food and Drug Administration (FDA), as part of the emergency use request it filed in October.
If Pfizer’s pill is authorized, there could be 2 Covid-19 pills by the end of the year that people could take at home to prevent infection and reduce the risk of hospitalization.
It may interest you:
* FDA approved the third dose of Pfizer against COVID-19 in the elderly and at risk
* WHO endorses Covaxin, a vaccine developed in India against Covid-19
* CDC Advisors Recommend Pfizer’s Covid-19 Vaccine for Children 5-11 Years